Should I buy or sell Editas Medicine stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares. View EDIT analyst ratings or view top-rated stocks .

What is Editas Medicine's stock price target for 2024?

9 equities research analysts have issued 1 year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts .

How have EDIT shares performed in 2024?

Editas Medicine's stock was trading at $10.13 at the beginning of 2024. Since then, EDIT shares have decreased by 45.2% and is now trading at $5.55. View the best growth stocks for 2024 here .

Are investors shorting Editas Medicine?

Editas Medicine saw a increase in short interest in March. As of March 31st, there was short interest totaling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is currently 8.9 days. View Editas Medicine's Short Interest .

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our EDIT earnings forecast .

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, February, 28th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.29. The company had revenue of $60 million for the quarter, compared to analysts' expectations of $4.84 million. Editas Medicine had a negative trailing twelve-month return on equity of 42.95% and a negative net margin of 196.12%. The company's quarterly revenue was up 817.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.88) earnings per share.

What ETFs hold Editas Medicine's stock?

ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , iShares Genomics Immunology and Healthcare ETF (IDNA) , Global X Genomics & Biotechnology ETF (GNOM) , Direxion Moonshot Innovators ETF (MOON) , Horizon Kinetics Medical ETF (MEDX) and AXS Green Alpha ETF (NXTE) . WisdomTree BioRevolution Fund (WDNA) .

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP) , NVIDIA (NVDA) , Micron Technology (MU) , Intellia Therapeutics (NTLA) , Block (SQ) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , QUALCOMM (QCOM) , Cisco Systems (CSCO) and Skyworks Solutions (SWKS) .

When did Editas Medicine IPO?

Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Baisong Mei, Bruce Eaton , Gilmore Neil O'neill, James C Mullen , Lisa Anne Michaels , Mark S Shearman and Michelle Robertson . View institutional ownership trends .

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EDIT

Editas Medicine (EDIT) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free EDIT Stock Alerts

$5.55

-0.06 (-1.07%)

(As of 04/18/2024 ET)

Compare

Today's Range: $5.51
▼
$5.68
50-Day Range: $5.61
▼
$11.07
52-Week Range: $5.51
▼
$11.91

Volume: 1.71 million shs
Average Volume: 1.82 million shs
Market Capitalization: $454.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Get Editas Medicine alerts:

Editas Medicine MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 170.3% Upside
$15.00 Price Target
Short Interest: Bearish
20.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: 0.44
Based on 3 Articles This Week
Insider Trading: Selling Shares
$924,582 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.61) to ($2.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars

Medical Sector

285th out of 918 stocks

Biological Products, Except Diagnostic Industry

40th out of 147 stocks

3.3

Analyst's Opinion

Consensus Rating
Editas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Editas Medicine has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
20.00% of the outstanding shares of Editas Medicine have been sold short.
Short Interest Ratio / Days to Cover
Editas Medicine has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in Editas Medicine has recently increased by 17.44%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Editas Medicine does not currently pay a dividend.
Dividend Growth
Editas Medicine does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Editas Medicine has received a 71.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Editas Medicine is -0.78.

1.9

News and Social Media Coverage

News Sentiment
Editas Medicine has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Editas Medicine this week, compared to 3 articles on an average week.
Search Interest
Only 18 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -51% compared to the previous 30 days.
MarketBeat Follows
18 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $924,582.00 in company stock.
Percentage Held by Insiders
Only 2.20% of the stock of Editas Medicine is held by insiders.
Percentage Held by Institutions
71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Editas Medicine are expected to decrease in the coming year, from ($2.61) to ($2.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Editas Medicine is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Editas Medicine is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Editas Medicine has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Editas Medicine Stock (NASDAQ:EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EDIT Stock News Headlines

April 18, 2024 | investing.com

Editas Medicine Inc (EDIT)

April 9, 2024 | finance.yahoo.com

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 13, 2024 | seekingalpha.com

Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

March 12, 2024 | seekingalpha.com

Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)

March 7, 2024 | fool.com

1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

March 6, 2024 | seekingalpha.com

Editas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)

March 4, 2024 | fool.com

1 Beaten-Down Stock With 55% Upside, According to Wall Street

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 2, 2024 | fool.com

Why Editas Medicine Stock Soared as Much as 42% Higher This Week

March 1, 2024 | markets.businessinsider.com

Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism

February 29, 2024 | markets.businessinsider.com

Hold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potential

February 29, 2024 | finance.yahoo.com

Q4 2023 Editas Medicine Inc Earnings Call

February 28, 2024 | msn.com

Editas Medicine files for mixed shelf offering

February 28, 2024 | marketwatch.com

Editas Medicine Shares Rally After Reni-cel Study Upgrade

February 28, 2024 | msn.com

Editas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32M

February 28, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Editas Medicine's earnings report

February 28, 2024 | finance.yahoo.com

Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials

February 28, 2024 | msn.com

Editas spikes as Vertex Pharma deal boosts Q4 topline

February 28, 2024 | globenewswire.com

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

February 27, 2024 | benzinga.com

Earnings Outlook For Editas Medicine

February 27, 2024 | msn.com

Editas Medicine Q4 2023 Earnings Preview

February 24, 2024 | finance.yahoo.com

EDIT Mar 2024 7.000 put

February 24, 2024 | ca.finance.yahoo.com

EDIT Mar 2024 12.000 call

February 21, 2024 | globenewswire.com

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

February 19, 2024 | finance.yahoo.com

Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade

February 13, 2024 | seekingalpha.com

Editas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)

See More Headlines

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:EDIT
CUSIP: N/A
CIK: 1650664
Web: www.editasmedicine.com
Phone: (617) 401-9000
Fax: N/A
Employees: 265
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $20.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +170.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.56
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-153,220,000.00
Net Margins: -196.12%
Pretax Margin: -196.12%
Return on Equity: -42.95%
Return on Assets: -30.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.39
Quick Ratio: 5.39

Sales & Book Value

Annual Sales: $78.12 million
Price / Sales: 5.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.27 per share
Price / Book: 1.30

Miscellaneous

Outstanding Shares: 81,810,000
Free Float: 80,014,000
Market Cap: $454.05 million
Optionable: Optionable
Beta: 2.01

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Gilmore O'Neill M.D. (Age 59)
President, CEO & Director
Comp: $815.37k
Dr. Baisong Mei M.D.
Ph.D., Senior VP & Chief Medical Officer
Dr. Feng Zhang Ph.D.
Co-Founder & Scientific Advisory Board Member
Dr. George McDonald Church Ph.D. (Age 70)
Co-Founder & Scientific Advisory Board Member
Dr. J. Keith Joung M.D.
Ph.D., Co-Founder & Scientific Advisory Board Member
Dr. David R. Liu Ph.D.
Co-Founder & Scientific Advisory Board Member
Mr. Erick J. Lucera C.F.A. (Age 56)
CPA, CFO & Executive VP
Dr. Linda C. Burkly Ph.D.
Executive VP & Chief Scientific Officer
Cristi Barnett
Corporate Communications & Investor Relations
Ms. Charlene Stern J.D.
Ph.D., Executive VP & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EDIT Stock Analysis - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares.
View EDIT analyst ratings or view top-rated stocks.
What is Editas Medicine's stock price target for 2024?: 9 equities research analysts have issued 1 year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price.
View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts.
How have EDIT shares performed in 2024?: Editas Medicine's stock was trading at $10.13 at the beginning of 2024. Since then, EDIT shares have decreased by 45.2% and is now trading at $5.55.
View the best growth stocks for 2024 here.
Are investors shorting Editas Medicine?: Editas Medicine saw a increase in short interest in March. As of March 31st, there was short interest totaling 16,360,000 shares, an increase of 17.4% from the March 15th total of 13,930,000 shares. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is currently 8.9 days.
View Editas Medicine's Short Interest.
When is Editas Medicine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our EDIT earnings forecast.
How were Editas Medicine's earnings last quarter?: Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, February, 28th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.29. The company had revenue of $60 million for the quarter, compared to analysts' expectations of $4.84 million. Editas Medicine had a negative trailing twelve-month return on equity of 42.95% and a negative net margin of 196.12%. The company's quarterly revenue was up 817.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.88) earnings per share.

What ETFs hold Editas Medicine's stock?: ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), Direxion Moonshot Innovators ETF (MOON), Horizon Kinetics Medical ETF (MEDX) and AXS Green Alpha ETF (NXTE).WisdomTree BioRevolution Fund (WDNA).
What other stocks do shareholders of Editas Medicine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).
When did Editas Medicine IPO?: Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who are Editas Medicine's major shareholders?: Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends.
How do I buy shares of Editas Medicine?: Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDIT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Editas Medicine (EDIT) Stock Price, News & Analysis

Editas Medicine MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Editas Medicine Stock (NASDAQ:EDIT)

EDIT Stock Price History

EDIT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EDIT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™